Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers E > Headlines for Endo Pharmaceuticals Holdings Inc. > News item |
Jefferies reiterates Endo Pharma at buy
Endo Pharmaceuticals Holdings Inc. was reiterated by Jefferies & Co., Inc. analyst David Windley at buy with a $35 price target on news of Opana's approval. This begins a new phase of earnings and growth for the company, according to the analyst. Endo raised 2006 revenue guidance by $20 million to $30 million after the approval. Shares of the Chadds Ford, Pa.-based pharmaceutical company were up $2.75, or 9.57%, at $31.50 on volume of 7,970,088 shares versus the three-month running average of 1,074,420 shares. (Nasdaq: ENDP)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.